Sandoz receives positive EU opinion for biosimilar filgrastim
- Details
- Category: Novartis
Sandoz has received a positive opinion from European regulators for its third biosimilar medicine, filgrastim, marking another important milestone in its efforts to bring affordable high-quality biopharmaceuticals to patients worldwide.
Johnson & Johnson Announces Definitive Agreement to Acquire Omrix
- Details
- Category: Financial
Johnson & Johnson (NYSE: JNJ) and Omrix Biopharmaceuticals, Inc. (NASDAQ: OMRI), a fully integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products, have announced a definitive agreement whereby Omrix will be acquired for approximately $438 million in a cash tender offer.
GSK and Neptunus form joint venture for the co-development of flu vaccines
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) has signed an exclusive Cooperation Agreement with Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. (NIBT) as a preliminary step in forming a Joint Venture (JV) between the two companies. The agreement outlines the proposed terms for establishing a JV company, which will seek to co-develop seasonal influenza vaccines and pre-pandemic/pandemic influenza vaccines, firstly targeting against strains of the virus specific to China, Hong Kong and Macau.
AstraZeneca to divest Nordic over-the-counter portfolio
- Details
- Category: AstraZeneca
AstraZeneca has announced the divestment to GlaxoSmithKline of a portfolio of over-the-counter (OTC) products predominantly sold in Sweden. The decision reinforces AstraZeneca's strategy to focus on innovation in prescription medicines.
Pfizer withdraws its application to change the marketing authorisation for Viagra
- Details
- Category: Pfizer
The European Medicines Agency (EMEA) has been formally notified by Pfizer Limited of its decision to withdraw its application for a change to the marketing authorisation for the medicine Viagra (sildenafil) 50 mg film-coated tablets.
AstraZeneca granted Temporary Restraining Order in PULMICORT RESPULES patent litigation
- Details
- Category: AstraZeneca
On 19 November 2008, AstraZeneca was granted a Temporary Restraining Order (TRO) by the United States District Court for the District of New Jersey, halting sales of Teva's budesonide inhalation suspension product, a generic version of AstraZeneca's PULMICORT RESPULES treatment.
Russia Chooses Inactivated Polio Vaccine from Sanofi Pasteur for Primary Immunization of All Infants
- Details
- Category: Sanofi
Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced that Russia has chosen inactivated polio vaccine (IPV) from Sanofi Pasteur for primary immunization of all infants. The IPV doses are provided by M.P. Chumakov Institute of Poliomyelitis and Virus Encephalitides through a manufacturing agreement with Sanofi Pasteur.
More Pharma News ...
- Pfizer Launches Global Regenerative Medicine Research Unit
- SEROQUEL XR and SEROQUEL Approved in Europe for New Indications
- Tarceva brings new hope to patients with advanced non-small cell lung cancer
- Bayer's Xarelto® Shows Encouraging Results in Patients with Acute Coronary Syndrome
- CRESTOR® is in line with other marketed statins - new data from the JUPITER study
- Genzyme and Osiris Partner to Develop and Commercialize First-in-Class Adult Stem Cell Products
- GlaxoSmithKline to acquire Genelabs Technologies to increase focus on novel small molecule therapies